Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Message To Wall Street: We're Doing Things Differently Now

Executive Summary

Three months after closing Pfizer's $68 billion acquisition of Wyeth (1"The Pink Sheet" DAILY, Jan. 26, 2009), Pfizer has already integrated both companies' R&D organizations and is now working to achieve steady, predictable, but diversified growth, CEO Jeff Kindler said at a Goldman Sachs health care conference Jan. 6

You may also be interested in...



Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical

With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations

Pfizer Lowers Targeted Revenues For 2012; Wall Street Remains Skeptical

With the Wyeth integration well under way, Pfizer did what analysts claimed it was going to do for months - it lowered its 2012 revenue targets to $66 billion-$68.5 billion from $70 billion, the figure it initially projected when it announced the Wyeth merger a year ago. But these figures still tower above Wall Street's expectations

Pfizer Lowers Targeted Revenues for 2012; Wall Street Remains Skeptical

Pfizer's touts growth plans in emerging markets as the pharma prepares for the onset of Lipitor generics.

Related Content

Topics

UsernamePublicRestriction

Register

PS051824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel